Disappointing trial results for Neostem

Neostem Inc. (Nasdaq: NBS) reported disappointing results from a trial of its cardiac stem cell therapy NBS10. Shares of the biotechnology firm plummeted $2.19 to $4.59.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.